DUBLIN, Oct. 25, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced a strategic investment in Novus Diagnostics, a company pioneering a rapid sepsis testing platform. This investment will accelerate the development and commercialization of Novus’ groundbreaking point-of-care diagnostic solutions, including its 15-minute bloodstream infection test. ...

DUBLIN, Oct. 25, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced the acquisition of EpiCapture Limited, a company developing a non-invasive test for monitoring the risk of aggressive prostate cancer. This acquisition marks Trinity Biotech’s strategic expansion into the oncology diagnostics market. Prostate cancer is the most common non-skin canc ...

Trinity Biotech plc (TRIB) has completed its first pre-pivotal clinical trial in Europe for its next-generation continuous glucose monitor (CGM). This trial assessed the effectiveness of significant technology enhancements since acquiring the CGM from Waveform Technologies in January 2024. The results confirm the progress in improving performance, usability and cost-efficiency, positioning Trinity Biotech for further advancements. CGMs are wearable devices that track real-time glucose levels using biosensor ...

DUBLIN, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced the successful completion of its first pre-pivotal clinical trial in Europe for its next-generation continuous glucose monitor (CGM) technology. The study assessed the analytical performance of CGM technology enhancements implemented by Trinity Biotech since acquiring the technolog ...

Trinity Biotech plc (TRIB) has announced the acquisition of privately held Irish deep-tech company Metabolomics Diagnostics. The acquired company specializes in the development of novel biomarker-based diagnostic solutions for complex diseases and is likely to improve diagnostic accuracy using mass spectrometry and machine learning for Trinity Biotech. Trinity Biotech's deal values Metabolomics Diagnostics at approximately $1.3 million. Trinity Biotech will pay the amount with just over 270,000 Trinity Biot ...

-Metabolomics Diagnostics, a deep-tech machine learning diagnostic platform developer, has developed an innovative test, PrePsia, to accurately predict the risk of preeclampsia in pregnant women- -The PrePsia test can predict preeclampsia risk as early as in the 12th week of pregnancy, allowing for early interventions to prevent serious health issues for mothers and their babies- -PrepSia will be commercialized in the U.S. market in 2025 through Trinity Biotech's New York-based Immco reference laboratory- D ...

文章核心观点 - 公司正在开发下一代连续血糖监测(CGM)技术,并计划在印度市场推出 [1][2][3] - 公司与拜耳公司签订了非约束性意向书,在中国和印度推出CGM设备 [2] - 公司正在进行印度市场的CGM使用情况调研,以优化产品设计 [2][3] - 公司计划通过低成本产品提高印度人群对CGM技术的可及性 [3] 公司概况 - 公司专注于人体诊断和糖尿病管理解决方案,包括可穿戴生物传感器 [1][5][6] - 公司开发、收购、制造和销售诊断系统,包括试剂和仪器 [5][6] - 公司最近收购了Waveform Technologies Inc.的生物传感器资产,并计划开发一系列生物传感器设备和相关服务,首款产品为连续血糖监测仪 [5][6] 行业概况 - 印度有超过1亿人患有糖尿病,1型和2型糖尿病均有上升趋势 [3] - 目前印度CGM使用率不高,但随着自我管理意识的提高而呈上升趋势 [3]

Trinity Biotech plc (TRIB) recently provided an update on its continued development of its glucose biosensor technology. Earlier this year, the company was granted a European patent for a novel method that enhances the performance of its glucose biosensor. Recent testing of this patented process has confirmed its effectiveness in improving the performance of the sensor. Trinity Biotech intends to use this breakthrough process to stabilize and improve the functionality of its glucose biosensor in its next-ge ...

DUBLIN, Ireland, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercialstage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today provided an update on the continued development of its glucose biosensor technology. Earlier this year Trinity Biotech was granted a European patent (EP3703565) for a novel method that enhances the performance of an indwelling sensor, such as a glucose biosensor. Recent testing of t ...

DUBLIN, Ireland, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercialstage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced that it has received substantial additional orders for TrinScreen HIV. As a result of this strong demand and the successful scaling of production capacity, the Company is now increasing its expected 2024 sales revenue for TrinScreen HIV to approximately $10 million, up from ...